- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05567588
Pembrolizumab Plus Radiotherapy for Advanced Renal Cancer
January 31, 2024 updated by: Nanfang Hospital, Southern Medical University
A Phase II,Single-arm Study to Evaluate the Safety and Efficacy of Pembrolizumab and Stereotactic Radiotherapy (SBRT) in Patients Advanced Metastatic Renal Clear Cell Carcinoma.
This study is designed as a phase-II proof of clinical trial to investigate if a treatment strategy where stereotactic body radiation therapy (SBRT) is given with pembrolizumab is sufficiently active to warrant further investigation in randomized phase II or III studies.
Metastatic renal cell cancer (mRCC) patients with PD-1 expressing immune cells are more likely to have larger more aggressive tumours and reduced survival.
Pembrolizumab is designed to directly block the interaction between PD-1 and its ligands, PD-L1 and PD-L2.
SBRT will be given to the 1-5 most clinically significant lesions after the 1nd course of pembrolizumab treatment in an effort to improve the activity of pembrolizumab.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
66
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Guozhu Xie
- Phone Number: 13242801662
- Email: xieguozhu@126.com
Study Locations
-
-
Guangdong
-
Guangzhou, Guangdong, China
- Recruiting
- Nanfang Hospital, Southern Medical University
-
Contact:
- Dehua Wu
- Phone Number: 020-62787693
- Email: 18602062748@163.com
-
Guangzhou, Guangdong, China
- Recruiting
- Guozhu,Xie
-
Contact:
- guozhu xie
- Phone Number: +8613242801662
- Email: xieguozhu@126.com
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Age> 18 years at the time of signing informed consent;
- ECOG score of 0 or 1;
- Histologically confirmed, advanced ccRCC of stage IV (AJCC 8);
- Life expectancy of more than 12 weeks;
- Evidence of measurable metastatic kidney cancer according to RECIST 1.1 criteria. Patients should have an adequate number of non-irradiated metastatic sites in order to adequately assess the activity of the pembrolizumab therapy;
- If central nervous system (CNS) metastases are treated before inclusion and the patient's neurological system is present Return of symptoms to baseline levels (except for signs or symptoms associated with CNS therapy)At least 14 days, such patients may be included. In addition, patients must stop taking glucocorticoids or prednisone in a stable dose and ≤ 10 mg per day;
Main organ function meets the following criteria within 7 days before treatment:
- blood examination criteria (in the state without blood transfusion within 14 days): ① Hemoglobin(HB) ≥ 70 g/L; ② Absolute Neutrophil Count(ANC) ≥ 1.0×109/L; ③ Platelet (PLT) ≥ 60×109/L.
- Biochemical examination shall meet the following criteria: ① total bilirubin within 1.5×the upper limit of normal(ULN); ② serum transaminase≤2.5×the Upper Limit of Normal(ULN), If associated with liver metastasis, serum transaminase≤5.0×the Upper Limit of Normal(ULN);③ serum creatine ≤ 1.5 x Upper Limit of Normal(ULN),creatinine clearance rate ≥ 60ml/min;
- Women of childbearing age should agree to use contraception (e. g. intrauterine device, contraceptive or condom) within 6 months after study completion, the pregnancy test results (serum or urine) within 7 days before enrolment must be negative;
- Men should agree that contraception must be used during and within 6 months of the end of the study period;
- With consent and have signed the informed consent, willing and able to comply with the planned visits, research treatment, laboratory tests, and other experimental procedures.
Exclusion Criteria:
- Has received prior therapy with an anti-PD-1, anti-PD-L1, anti-PD-L2;
- Any active or recently diagnosed clear or suspected autoimmune disorder disease, or symptoms requiring glucocorticoids (> 10 mg/day) or immunosuppressive drugs for systemic therapy;
- Active brain metastases and/or cancerous meningitis;
- Has had a prior monoclonal antibody within 4 weeks prior to the first dose of trial treatment or who has not recovered (i.e., ≤ Grade 1 or at baseline) from adverse events due to agents administered more than 4 weeks earlier;
- Has more than one previous chemotherapy,targeted small molecule therapy, or radiation therapy within 2 weeks prior to the first dose of trial treatment or who has not recovered (i.e., ≤ Grade 1 or at baseline) from adverse events due to a previously administered agent;
- Diagnosed with immunodeficiency within 2 weeks prior to study or being treated with systemic glucocorticoids or any other form of immunosuppressive therapy;
- Have a positive history of human immunodeficiency virus (HIV) test or have acquired immunodeficiency syndrome (AIDS);
- Has known active Hepatitis B or Hepatitis C;
- Has a known additional malignancy that is progressing or requires active treatment;
- Have interstitial lung disease, active pulmonary infectious pneumonia, or grade 3 or higher pneumonia;
- Patients with mental or physical illnesses (such as infectious diseases) requiring compulsory isolation treatment;
- Has received a live vaccine within 30 days prior to the first dose of trial treatment; · · According to the investigator, there may be increased risk associated with participation in the study, or other severe, acute or chronic medical or psychiatric disorders that may interfere with the interpretation of the findings.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Pembrolizumab + RT (5 fractions, 8 Gy) + Pembrolizumab
Pembrolizumab will be started. Stereotactic Body Radiation Therapy will be given before the 2nd course of pembrolizumab and pembrolizumab will be continued. Pembrolizumab will continue until progression as per immune related response criteria (irRC). |
200mg(body weight >75kg) or 100mg(body weight≤75kg) given intravenously over 30 minutes day 1 of every 3 week cycle until progression as per immune related response criteria.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
ORR
Time Frame: Approximately 2 months
|
Objective response rate by immune related response criteria (irRC), and RECIST 1.1 criteria
|
Approximately 2 months
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Overall survival
Time Frame: up to 24 months
|
up to 24 months
|
Number of participants with treatment-related adverse events as assessed by CTCAE v5.0
Time Frame: up to 24 months
|
up to 24 months
|
The disease control rate
Time Frame: up to 24 months
|
up to 24 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
October 31, 2022
Primary Completion (Estimated)
October 31, 2024
Study Completion (Estimated)
October 31, 2025
Study Registration Dates
First Submitted
October 2, 2022
First Submitted That Met QC Criteria
October 2, 2022
First Posted (Actual)
October 5, 2022
Study Record Updates
Last Update Posted (Estimated)
February 1, 2024
Last Update Submitted That Met QC Criteria
January 31, 2024
Last Verified
January 1, 2024
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Neoplasms by Histologic Type
- Neoplasms
- Urologic Neoplasms
- Urogenital Neoplasms
- Neoplasms by Site
- Kidney Diseases
- Urologic Diseases
- Adenocarcinoma
- Neoplasms, Glandular and Epithelial
- Kidney Neoplasms
- Female Urogenital Diseases
- Female Urogenital Diseases and Pregnancy Complications
- Urogenital Diseases
- Male Urogenital Diseases
- Carcinoma, Renal Cell
- Carcinoma
- Molecular Mechanisms of Pharmacological Action
- Antineoplastic Agents
- Antineoplastic Agents, Immunological
- Immune Checkpoint Inhibitors
- Pembrolizumab
Other Study ID Numbers
- NFEC-2022-248
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
Yes
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Clear-cell Metastatic Renal Cell Carcinoma
-
City of Hope Medical CenterNational Cancer Institute (NCI)Active, not recruitingMetastatic Renal Cell Carcinoma | Metastatic Clear Cell Renal Cell Carcinoma | Advanced Clear Cell Renal Cell Carcinoma | Stage III Renal Cell Cancer AJCC v8 | Stage IV Renal Cell Cancer AJCC v8 | Metastatic Sarcomatoid Renal Cell Carcinoma | Advanced Renal Cell Carcinoma | Unresectable Renal Cell... and other conditionsUnited States
-
Celldex TherapeuticsTerminatedKidney Neoplasms | Metastatic Renal Cell Carcinoma | Ovarian Clear Cell Carcinoma | Papillary Renal Cell Carcinoma | Renal Cell Carcinoma (RCC) | Clear-cell Renal Cell CarcinomaUnited States
-
Association Pour La Recherche des Thérapeutiques...CompletedClear-cell Metastatic Renal Cell Carcinoma | Clear-cell Renal CarcinomaFrance
-
Millennium Pharmaceuticals, Inc.CompletedClear-cell Metastatic Renal Cell CarcinomaSpain, Czechia, United States, Canada, Italy, United Kingdom, France, Poland
-
Rennes University HospitalCompletedMetastatic Clear Cell Renal Cell CarcinomaFrance
-
Radboud University Medical CenterCompletedMetastatic Clear Cell Renal Cell CarcinomaNetherlands
-
Celldex TherapeuticsTerminatedNeoplasms | Neoplasms by Histologic Type | Kidney Neoplasms | Carcinoma, Renal Cell | Urologic Neoplasms | Urogenital Neoplasms | Kidney Diseases | Urologic Diseases | Clear-cell Metastatic Renal Cell CarcinomaUnited States
-
Australian and New Zealand Urogenital and Prostate...Merck Sharp & Dohme LLC; AmgenActive, not recruitingRenal Cell Carcinoma, Clear Cell | Metastatic Kidney CancerAustralia
-
University of Texas Southwestern Medical CenterTerminatedMetastatic Clear Cell Renal Cell CarcinomaUnited States
-
Abramson Cancer Center of the University of PennsylvaniaUniversity of Pittsburgh; Rutgers Cancer Institute of New JerseyCompletedMetastatic Clear Cell Renal Cell CarcinomaUnited States
Clinical Trials on Drug: Pembrolizumab
-
OncXerna Theraputics, Inc.Merck Sharp & Dohme LLCCompletedGastric Cancer | GastroEsophageal CancerKorea, Republic of, United Kingdom, Taiwan, United States
-
InventisBio Co., LtdMerck Sharp & Dohme LLCActive, not recruitingNSCLC | Solid Tumor, Adult | CRCUnited States, Taiwan, Australia, Korea, Republic of
-
Peking University Cancer Hospital & InstituteNot yet recruitingMucosal Melanoma | Neoadjuvant TreatmentChina
-
Peking UniversityMerck Sharp & Dohme LLC; Cancer Institute and Hospital, Chinese Academy of... and other collaboratorsRecruitingStage IIIA Non-small Cell Lung Cancer | Stage IIA Non-small Cell Lung Cancer | Stage IIB Non-small Cell Lung Cancer | Stage IIIB(N2) Non-small Cell Lung CancerChina
-
Translational Research in OncologyBayerRecruitingCarcinoma, HepatocellularSpain, Taiwan, Japan, United States, Korea, Republic of, Georgia, Germany, France, Turkey, Italy, Belgium, Hong Kong, Serbia
-
University Medical Center GroningenCompleted
-
Incyte CorporationMerck Sharp & Dohme LLCCompletedMelanomaUnited States, France, Italy, United Kingdom, Spain, Belgium, Israel, Mexico, Japan, Canada, Netherlands, Sweden, Korea, Republic of, Australia, Russian Federation, Chile, Germany, Poland, Ireland, New Zealand, Denmark, Switzerland, South Africa
-
Merck Sharp & Dohme LLCCompletedMelanomaAustralia, South Africa, Spain, Sweden
-
Acerta Pharma BVMerck Sharp & Dohme LLCCompletedMetastatic Urothelial CarcinomaUnited States
-
The Central Hospital of Lishui CityNot yet recruiting